Clinical Trials on HIV-1 in Canada

Total 1212 results

Canadian Immunodeficiency Research Collaborative
Hoffmann-La Roche

Completed

Fuzeon Viral Decay Pilot Study

HIV-1

Canada
University of Alberta
University of British Columbia; Gilead Sciences

Terminated

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

HIV-1-infection

Canada
Mylan Inc.
ViiV Healthcare

Completed

Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)

HIV-1-infection

Canada
University Health Network, Toronto
CIHR Canadian HIV Trials Network

Terminated

Probiotic Visbiome for Inflammation and Translocation in HIV Ι (PROOV IT I)

HIV-1 Infection

Canada
University Health Network, Toronto
CIHR Canadian HIV Trials Network

Unknown

Probiotic Visbiome for Inflammation and Translocation in HIV II (PROOV IT II)

HIV-1 Infection

Canada
University Hospital Virgen de las Nieves

Unknown

Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients (DOLAVI)

HIV-1-infection

Spain
Mount Sinai Hospital, Canada
CIHR Canadian HIV Trials Network

Unknown

Progesterone Supplementation for HIV-positive Pregnant Women on Anti-Retrovirals (ProSPAR)

HIV-1 Infection

Canada
GlaxoSmithKline

Terminated

Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects

HIV-1

Australia, Belgium, Canada, France, Germany, Greece, Italy, Spain, United Kingdom
Tibotec Pharmaceuticals, Ireland

Completed

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

HIV-1

United States, Canada, France, Belgium, Germany, Spain, Argentina, Chile, Panama, Brazil, Puerto Rico, Thailand, Mexico, Australia
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

HIV-1

United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
Gilead Sciences

Active, not recruiting

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2- Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

HIV-1

United States, Panama, South Africa
Hospitales Universitarios Virgen del Rocío

Completed

Etravirine Plus 2 Analogs in HIV-infected Patients

HIV-1-infection

Spain
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine (MERIT)

HIV-1

United States, Canada, United Kingdom, Netherlands, Argentina, Australia, Belgium, South Africa, Switzerland, Italy, Puerto Rico, Brazil, Mexico, Poland
Pfizer

Completed

A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1

HIV-1

United Kingdom, South Africa, Australia, Canada, Italy, Poland, Switzerland, Argentina, Mexico
ViiV Healthcare
Pfizer

Terminated

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 (MODERN)

HIV-1

United States, Netherlands, Spain, Puerto Rico, Canada, Australia, Germany, Sweden, Poland, Portugal, Switzerland, France, Denmark, Italy, Belgium, United Kingdom, Hungary, Austria, Finland
Tibotec Pharmaceuticals, Ireland

Completed

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

HIV-1

United States, Belgium, Germany, Taiwan, Spain, Mexico, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Korea, Republic of, Russian Federation, Puerto Rico, Luxembourg
Pfizer
ViiV Healthcare

Terminated

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

HIV-1

South Africa, Australia, United Kingdom, Canada, Italy, Poland, Switzerland, Mexico, Brazil
Gilead Sciences

Active, not recruiting

Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (BIC-STaR)

HIV-1-infection

Canada
Janssen Sciences Ireland UC

Completed

TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV

HIV-1 Infections

Costa Rica, Panama, South Africa, Ukraine, Malaysia, Brazil, Thailand, Guatemala
Ottawa Hospital Research Institute
Pfizer

Completed

A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc (RIFAMARA)

HIV Infection | HIV-1 Infection | Mycobacterium Avium Complex (MAC)

Canada
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

HIV-1 Infection

Spain, United Kingdom, Sweden, Germany, United States, France, Belgium, Ireland, Italy, Denmark, Puerto Rico, Canada
Gilead Sciences

Completed

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

HIV-1 Infection

Spain, United States, France, Italy, Germany, Canada, United Kingdom, Belgium, Puerto Rico, Australia
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

HIV-1 Infection

United States, United Kingdom, Canada, France, Italy, Puerto Rico, Belgium
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Spain, United States, Italy, Germany, United Kingdom, France, Australia, Puerto Rico, Canada, Belgium, Dominican Republic
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

HIV-1 Infection

United States, Spain, United Kingdom, Canada, Puerto Rico, France, Belgium, Italy, Germany, Austria
Bristol-Myers Squibb

Terminated

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

HIV-1 Infection

Thailand, United States, Australia, Canada, Spain, Colombia, South Africa, Hungary, France, Peru, Argentina, Chile, Mexico
Gilead Sciences

Completed

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

HIV-1 Infection

United States, Spain, United Kingdom, Netherlands, Germany, Canada, Sweden, Switzerland, Italy, Belgium, Puerto Rico, France
Gilead Sciences

Completed

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

HIV-1-infection

United States, Puerto Rico, France, Germany, Austria, Canada
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Canada, United States, Puerto Rico, Spain, United Kingdom, France, Portugal, Netherlands, Belgium, Italy, Australia, Austria, Germany, Switzerland
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

France, Spain, Germany, United Kingdom, United States, Puerto Rico, Belgium, Canada, Italy, Dominican Republic
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, France, Germany, United Kingdom, Italy, Canada, Australia, Belgium, Puerto Rico, Dominican Republic
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, United Kingdom, Switzerland, Germany, Canada, France, Belgium, Puerto Rico
Janssen R&D Ireland

Completed

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

HIV-1 Infection

United States, Australia, France, United Kingdom, China, Belgium, Germany, Spain, Argentina, Romania, South Africa, Canada, Denmark, Netherlands, Chile, Puerto Rico, Austria, Russian Federation, Thailand, Sweden, Taiwan
Gilead Sciences

Recruiting

Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

HIV-1-infection

United States, France, Canada
McMaster University
CIHR Canadian HIV Trials Network

Completed

Estrogen, Probiotics and Vaginal Health to Prevent HIV Infection in ACB Women

HIV-1-infection | Bacterial Vaginoses

Canada
Columbia University
National Institute on Drug Abuse (NIDA); University of Miami; Weill Medical College... and other collaborators

Recruiting

Integrated HIV Prevention and HCV Care for PWID (M2HepPrEP)

HIV Prevention | Opioid Use | HCV | Intravenous Drug Usage

Canada, United States
Gilead Sciences

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

HIV-1-infection

United States, Spain, France, Taiwan, Japan, Thailand, Dominican Republic, Germany, Canada, Italy, South Africa
Saskatchewan Health Authority - Regina Area
Gilead Sciences

Unknown

Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy

Hepatitis C, Chronic | HIV/AIDS | Bone Diseases, Metabolic | Opioid Dependence | HIV-1-infection | HCV Coinfection | Buprenorphine Dependence | Methadone Dependence | Co-infection

Canada
Centre for Addiction and Mental Health
CAMH Foundation

Completed

Evaluation of the Healthy Relationships Plus Program for Youth

Mental Health Wellness 1

Canada
University of Guelph

Recruiting

Strengths to Grow - Preteen: An Online Parenting Resource

Mental Health Wellness 1

Canada
University of Alberta
CASA: Child, Adolescent and Family Mental Health

Completed

Mindfulness-based Stress Reduction for Pediatric Mental Health (MBSR)

Mental Health Wellness 1

Canada
McGill University

Recruiting

The Online Mood Booster Challenge to Support Physical and Mental Health

Mental Health Wellness 1

Canada
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Spain, Canada, United Kingdom, South Africa, Japan
University of Saskatchewan
The Hospital for Sick Children; University of Calgary; Children's Hospital of...

Recruiting

Canadian Bone Strength Development Study (CanBSDS)

Type-1 Diabetes

Canada
The Hospital for Sick Children
The Lawson Foundation

Completed

An Evaluation of Internet-based Carbohydrate Counting Education for Adolescents With Type 1 Diabetes

Type 1 Diabetes Mellitus

Canada
Institut de Recherches Cliniques de Montreal

Completed

Carbohydrate-based Strategies to Prevent Exercise-induced Hypoglycemia

Type 1 Diabetes Mellitus

Canada
Institut de Recherches Cliniques de Montreal
McGill University Health Centre/Research Institute of the McGill University...

Recruiting

Insulin-based Strategies to Prevent Hypoglycemia During Two Types of Exercise (RIDE-2)

Type 1 Diabetes Mellitus

Canada
Institut de Recherches Cliniques de Montreal

Active, not recruiting

Electrocardiographic Modifications and Spontaneous Hypoglycemic Episodes in Type 1 Diabetes

Type 1 Diabetes Mellitus

Canada
LMC Diabetes & Endocrinology Ltd.

Unknown

Flexible Insulin Therapy Untethered Insulin Regimen in Avidly Exercising Patients With Type 1 Diabetes: FIT Untethered (FIT Untethered)

Type 1 Diabetes Mellitus

Canada
University of Calgary
Canadian Diabetes Association

Completed

Assessment of an Alternative Model of Follow-up of Children and Adolescents With Type 1 Diabetes

Type 1 Diabetes Mellitus

Canada

3

Subscribe